Tenax Posts Wider Loss in Fiscal Q2
Tenax Therapeutics (NASDAQ:TENX), a development-stage biopharmaceutical company focused on treatments for cardiovascular and pulmonary diseases, released its results for the second quarter of fiscal 2025 on August 13, 2025. The company posted a GAAP EPS loss of $(0.27) for Q2 2025, and reported a GAAP net loss of $10.85 million for Q2 2025. Total operating expenses (GAAP) rose sharply in Q2 2025 versus Q2 2024, while the company maintained its status as a pre-commercial entity with no revenue. Cash and cash equivalents totaled $105.5 million as of June 30, 2025, providing a multi-year funding runway. The quarter showed continued pipeline progress but no new clinical or regulatory data. Overall, the period featured expanding clinical and operational efforts, significant cost increases, and a stable financial position that supports the company’s ongoing trials.
Source: Analyst estimates for the quarter provided by FactSet.
Tenax Therapeutics develops advanced therapies for serious cardiovascular and pulmonary conditions. Its lead programs target pulmonary hypertension in patients with heart failure with preserved ejection fraction (PH-HFpEF), a disease area with limited treatment options.
Source Fool.com
